Filter posts

Discrimination Against Vulnerable Patients Is Nothing New

Transformative therapies are advancing like never before, and a new class of medicines are changing …

Peter Pitts Examines the Role of PBMs and their Deceptive Tactics

A piece by Peter J. Pitts, a former FDA Associate Commissioner and President of the …

Kentucky Officials Expose PBMs for Gaming the System

While many were watching the drug pricing debate unfold on Capitol Hill, the Kentucky Cabinet …

Greenwood Shines Spotlight on Insurance Industry Rip-off

Writing for The Hill, BIO’s President and CEO Jim Greenwood shined a spotlight on a …

Another Year, Another Misleading Insurance Company Report

Once again, Blue Cross Blue Shield is out with a report attempting to stoke fear …

Watchdog Report Reaffirms Concerns With Fail First

A new report by the Office of Inspector General at the U.S. Department of Health …

Hits to Patients Keep on Coming

At a time when prescription drug prices and spending are remarkably stable, patients are getting …

Report: Patients More Likely to Skip Therapy as Out-of-Pocket Costs Rise

IQVIA — a nonpartisan health care research firm — is out with troubling new data …

PBS NewsHour: Why a Patient Paid a $285 Copay for a $40 Drug

A featured story by PBS NewsHour reaffirms that insurance companies and drug cost middlemen determine …

As Out-of-Pocket Costs Rise, Insurers Spend Big on Administrative Costs

It seems every week the insurance industry is busy pointing the finger at biopharmaceutical innovators …